Compare FuelCell Energy Inc (FCEL) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FuelCell Energy Inc vs Recursion Pharmaceuticals Inc — how do they compare? FuelCell Energy Inc trades at $16.94 (market cap $1.47B), while Recursion Pharmaceuticals Inc trades at $3.93 (market cap $2.14B). The key difference: Recursion Pharmaceuticals Inc is the larger of the two by market cap, and Recursion Pharmaceuticals Inc is more actively traded (30,789,535 versus 12,559,948). Which is the better fit depends on your goals — on Pluang, investors hold FuelCell Energy Inc for 48 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| FCEL | RXRX | |
|---|---|---|
Market Cap | $1.47B | $2.14B |
Volume | 12,559,948 | 30,789,535 |
Sector | Industrials | Health |
52-Week High | $36.01 | $6.79 |
52-Week Low | $6.00 | $2.84 |
Typical Hold Time | 48 Days | 22 Days |
Enterprise Value | $1.05B | $1.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FuelCell Energy (FCEL) trades at $18.365, down 11.07% over 24 hours, with a bullish technical signal from moving averages but neutral oscillators. The company reported revenue of $158.16M in 2025 but posted a net loss of $187.90M, with negative gross and net income margins. Recent news highlights a securities class action lawsuit filed against the company, alleging misleading disclosures between June and September 2026.
FCEL faces significant financial challenges with persistent losses and negative cash flow from operations, though analyst consensus suggests a $21.57 price target with 40% buy ratings. Investment opportunities exist if the company achieves profitability, but risks include ongoing litigation, execution risks in scaling operations, and competitive pressures in the clean energy sector.
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About FuelCell Energy Inc
FuelCell Energy Inc is a fuel-cell power company. FuelCell designs manufactures, sells, installs, operates, and services fuel cell products, which efficiently convert chemical energy in fuels into electricity through a series of chemical reactions. It serves various industries such as Industrial, Wastewater treatment, Commercial and Hospitality, Data centers and Communications, Education and Healthcare, and others. Geographically, the company generates a majority of its revenue from the United States followed by South Korea.
Read more on FCEL →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
